Allows terminally ill patients in Hawaii to access investigational drugs or biological products.

The bill allows terminally ill patients in Hawaii to access investigational drugs or biological products that have completed phase one of clinical trials but are not yet approved for general use. Patients must meet specific criteria, including having a terminal illness, considering all approved treatments, and providing informed consent. The bill also protects patients' heirs from liability if they die during treatment and ensures health care providers' licenses are not affected. It takes effect on January 1, 2026.

Allows terminally ill patients in Hawaii to access investigational drugs or biological products.

The bill allows terminally ill patients in Hawaii to access investigational drugs or biological products that have completed phase one of clinical trials but are not yet approved for general use. Patients must meet specific criteria, including having a terminal illness, considering all approved treatments, and providing informed consent. The bill also protects patients' heirs from liability if they die during treatment and ensures health care providers' licenses are not affected. It takes effect on January 1, 2026.